Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
IMDEVIMAB (im DEV i mab) is a monoclonal antibody. It is used with another monoclonal antibody to treat COVID-19 in patients who are not hospitalized. It is also used to reduce the risk of getting COVID-19. It is for patients at risk of getting severe symptoms of COVID-19. It may decrease the risk of developing severe symptoms of COVID-19. It may also decrease the chance of going to the hospital. This medicine is not approved by the FDA. The FDA has authorized emergency use of this medicine during the COVID-19 pandemic.
This drug is for infusion into a vein or injected under the skin. It is given by a health care provider in a clinic setting.
Talk to your pediatrician regarding the use of this drug in children. While this drug may be prescribed for children as young as 12 years of age for selected conditions, precautions do apply.
Side effects that you should report to your doctor or health care professional as soon as possible:
Side effects that usually do not require medical attention (report these to your doctor or health care professional if they continue or are bothersome):
This drug is given in a clinic and will not be stored at home.
They need to know if you have any of these conditions:
Keep appointments for follow-up doses. It is important not to miss your dose. Call your health care provider if you are unable to keep an appointment.
Your condition will be monitored carefully while you are receiving this drug. Visit your health care provider for regular checkups. Tell your health care provider if your symptoms do not start to get better or if they get worse.
After receiving this medicine, wait at least 90 days before getting the COVID-19 vaccine. If you have already received your first dose of the COVID-19 vaccine, wait at least 90 days after getting this medicine before getting your second dose of vaccine.
Cookies são usados neste site. Para recusar ou saber mais, visite nosso cookies page.